Clinical Scorecard: T Cell Immune Responses to Chlamydia trachomatis Indicate Broad Exposure Among South African Adolescents and Young Women
At a Glance
Category
Detail
Condition
Chlamydia trachomatis infection
Key Mechanisms
CD4+ T cell-mediated Th1 cytokine responses; mucosal inflammation and systemic immunity interplay
Target Population
Adolescent girls and young women (AGYW), 16–22 years old, South Africa
Care Setting
Sexual health clinics and research settings in low-and-middle income countries
Key Highlights
High prevalence of C. trachomatis infection among South African AGYW with varied exposure histories.
NAAT+/Ab+ status (untreated/recurrent infection) linked to increased cervical T cell activation but lower magnitude of systemic C. trachomatis-specific CD4+ T cell responses.
Protective immunity correlates with higher multifunctional CD4+ T cell responses and inverse relationship between systemic Th1 responses and genital tract inflammatory cytokines.
Guideline-Based Recommendations
Diagnosis
Use nucleic acid amplification testing (NAAT) and serology to stratify infection and exposure status.
Screen AGYW regularly due to high asymptomatic infection rates.
Management
Offer antibiotic treatment promptly to NAAT-positive individuals and provide partner referral letters.
Consider prevention strategies emphasizing vaccine development to reduce infection burden.
Monitoring & Follow-up
Monitor cervical T cell activation and systemic CD4+ T cell responses to assess infection status and immune protection.
Track genital tract cytokine levels (IL-1β, TNF, IL-17A) as markers of mucosal inflammation.
Risks
Untreated or recurrent infections may increase mucosal immunopathology and risk of pelvic inflammatory disease and infertility.
Live-attenuated vaccines may induce genital tract pathology and increase HIV-1 acquisition risk.
Patient & Prescribing Data
South African adolescent girls and young women with varying C. trachomatis exposure and infection status
Effective antibiotic treatment is available but many infections remain undiagnosed and untreated; immune responses vary by infection history affecting potential vaccine efficacy.
Clinical Best Practices
Exclude participants with confounding factors such as HIV infection, pregnancy, menstruation, recent antibiotic use, or recent vaginal interventions when assessing immune responses.
Use multiparameter flow cytometry to characterize C. trachomatis-specific CD4+ T cell responses.
Stratify patients by NAAT and serology status to differentiate primary, cleared, and recurrent infections.
Incorporate both mucosal and systemic immune assessments to inform vaccine development and prevention strategies.
by Rubina Bunjun, Micaela Lurie, Smritee Dabee, Shaun Barnabas, Venessa Maseko, Shameem Z Jaumdally, Hoyam Gamieldien, David A Lewis, Heather B Jaspan, Katherine Gill, Linda-Gail Bekker, Jo-Ann S Passmore
